Condition
Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Malignant Rhabdoid Tumors (MRT)|Rhabdoid Tumors of the Kidney (RTK)|Atypical Teratoid Rhabdoid Tumors (ATRT)|Synovial Sarcoma|Epitheliod Sarcoma|Mesothelioma|Advanced Solid Tumors
Estimated Enrollment: 300
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: EZH-501
Study First Received: August 5, 2016
Last Updated: September 13, 2016
Estimated Primary Completion Date: December 2023
Primary Outcome Measures:
Long-term safety profile of tazemetostat measured by number of AEs and duration of exposure to tazemetostat|The overall survival (OS)
Sponsors and Collaborators:
Epizyme, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT02875548
